SEC EDGARSEP 181 min read$UTHR

MAHON PAUL A sold $4.1M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $497.54 ($495.97–$501.58, $4.13M total) across 7 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · MAHON PAUL A

Published Sep 18, 2026, 8:40 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 18, 2026, 8:55 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$UTHR

Bearish

medium confidence

Mentioned

$UTHR

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$UTHRBearishLow

Why it matters

Provides fresh data on insider sentiment, useful for short‑term trading decisions.

Market read

Insider sell may influence short‑term price action but is unlikely to drive long‑term trends.

What to watch

Potential upcoming clinical data releases that could offset sell pressure.

Relevance 5/10Novelty 4/10Timing: sale executed on 2026-09-17

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$UTHRBearishMedium confidence

Context

Insider Paul Mahon sold 8,300 shares for $4.13M via a 10b5-1 plan, reducing his stake to 45,172 shares.

Expected impact

Potential short-term dip of 1-2% as market digests the insider sell.

Evidence & confidence

A $4M sale by an EVP is material for a mid‑cap biotech, but the size relative to float is limited.

Market effects

Sector

May prompt scrutiny of other insider holdings in the biotech sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

Officer
Paul Mahon
EVP & General Counsel of United Therapeutics

Read at source ← All news

SEP 11

$UTHRHigh

United Therapeutics Moves to Complete Its $2 Billion Buyback, Betting the Market Is Underpricing Its Pipeline

United Therapeutics (UTHR) announced a $477.6M accelerated share repurchase agreement with Citibank, completing its $2B buyback program. CEO Martine Rothblatt stated the move reflects confidence in the company's undervalued pipeline. The company has returned $4B to shareholders in 2.5 years.

biobuzz.io2 min

SEP 11

$UTHRHigh

United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace?

United Therapeutics (UTHR) committed $477.6M to a share repurchase, part of its $2B authorization. The company has $3.8B in cash and investments, with pending FDA reviews for ralinepag and Nebulized Tyvaso. Q2 revenue declined 2% to $783.3M, with Tyvaso revenue down 4%. The buyback's impact on shareholder value depends on pipeline success and cash generation.

insidermonkey.com2 min

SEP 10

$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min

SEP 9

$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min

SEP 9

$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min

SEP 8

$UTHRHighAI 8/10

United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi

United Therapeutics (UTHR) agreed to repurchase $477.6M of its common stock through an accelerated share repurchase with Citi. The company will pay upfront and receive an initial 719,376 shares, with final count based on average daily VWAP. Settlement is expected in Q4 2026.

tradingview.com1 min